We serve Chemical Name:2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile CAS:84803-57-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile
CAS.NO:84803-57-6
Synonyms:(4-tert-butyl-2,6-dimethyl-phenyl)-acetonitrile;EINECS 284-183-4;(4-tert-Butyl-2,6-dimethyl-phenyl)-acetonitril
Molecular Formula:C14H19N
Molecular Weight:201.30700
HS Code:2926909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:302.5ºC at 760 mmHg
Density:0.936g/cm3
Index of Refraction:1.505
PSA:23.79000
Exact Mass:201.15200
LogP:3.66698
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (4-tert-butyl-2,6-dimethyl-phenyl)-acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-tert-Butyl-2,6-dimethyl-phenyl)-acetonitril physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-tert-butyl-2,6-dimethyl-phenyl)-acetonitrile Use and application,EINECS 284-183-4 technical grade,usp/ep/jp grade.
Related News: The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile manufacturer The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile supplier The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this. 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile vendor Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.
